Xortx reports proxy firms recommend shareholders vote ‘FOR’ share consolidation

XORTX Therapeutics (XRTX) announce that independent proxy advisory firms, including Institutional Shareholder Services have recommended shareholders vote “FOR” on the share consolidation at the upcoming shareholder meeting scheduled for March 24, 2026. In relation to the Share Consolidation, ISS recommended voting FOR this resolution stating: “…the stock consolidation should have no direct impact on shareholder value and could enhance the long-term growth prospects of the Company by broadening its financing alternatives.” Dr. Allen Davidoff, CEO and XORTX, stated, “We are pleased to receive the news that an independent third-party proxy advisory firm, ISS, has recommended shareholders vote FOR all of the proposed resolutions. This endorsement truly underscores the strength of our proposals and affirms their alignment with shareholder interests. We appreciate the support and confidence expressed by these respected advisory firms.”